We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab.
The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation’ was presented at the 2021 ASCO Annual Meeting.
Abstract number: TPS8052Â
DOI: 10.1200/JCO.2021.39.15_suppl.TPS8052 Journal of Clinical Oncology 39, no. 15_suppl
Questions
1. What are the potential advantages and challenges of developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab? (0:15-02:00)
2. What are the aims of the EQUATE trial and which patients will be eligible for enrolment? (02:00-03:30)
3. Could you tell us a little about the randomized biomarker-stratified design of the study? (03:30-04:32)
4. How have the subgroup sizes been calculated and what is the total accrual goal? (04:32-05:33)
5. What is the primary endpoint of the study? (05:33-06:36)
Disclosures: Dr Shaji Kumar discloses research funding for clinical trials to his institution from Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda and Tenebio. He also discloses consulting and advisory board participation (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca and Bluebird Bio; and with personal payment for Oncopeptides, Beigene, Antengene.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the 2021 ASCO Annual Meeting.
